Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

BACKGROUND: A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using FOLFIRI.3 and gemcitabine alternately (Arm 2) compared to gemcitabine alone (Arm 1) in patients with metastatic non pre-treated pancreatic adenocarcinoma. The primary endpoint was the...

Descripción completa

Detalles Bibliográficos
Autores principales: Anota, Amélie, Mouillet, Guillaume, Trouilloud, Isabelle, Dupont-Gossart, Anne-Claire, Artru, Pascal, Lecomte, Thierry, Zaanan, Aziz, Gauthier, Mélanie, Fein, Francine, Dubreuil, Olivier, Paget-Bailly, Sophie, Taieb, Julien, Bonnetain, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444351/
https://www.ncbi.nlm.nih.gov/pubmed/26010884
http://dx.doi.org/10.1371/journal.pone.0125350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444351/
https://www.ncbi.nlm.nih.gov/pubmed/26010884
http://dx.doi.org/10.1371/journal.pone.0125350

Ejemplares similares